You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Biomimetic Slope Adaptive Foot-Ankle Prosthesis
SBC: MOTION CONTROL, INC Topic: DHP16C007The primary objectiveis to develop acommercially-viable prototype of theslopeadaptive prosthesis design and to iteratively improvethe design based on ISO standards testingand rigorous usein human subject field trials. The proposed work will build upon knowledgegained in PhaseI of the project,which established feasibility for this design approach in alightweight, passive hydraulicfoot-anklesystem. ...
STTR Phase II 2022 Department of DefenseDefense Health Agency -
Cervical Spine Health Improvement Products
SBC: SWITCHBOX INC Topic: DHA18B001Neck pain isacommon and disabling health impairmentaffecting both militaryand civilian populations. Dueto alack of objective,reliable,and actionablemetrics, occupational interventionsand treatment plansaretypically based on atrial-and error process that results in suboptimal outcomesand inflated costs. To address this problem, our objective will beto (1) develop an evidence-based technology that l ...
STTR Phase II 2022 Department of DefenseDefense Health Agency -
Urocortin-2 Gene Transfer for Type 1 Diabetes and Associated LV Dysfunction
SBC: Renova Therapeutics, Inc. Topic: NHLBIABSTRACT Type-1 Diabetes Mellitus (T1DM) affects 1.25 million patients in US with 40,000 new patients annually. Lifespan is shortened 11-13 years, due to kidney and heart disease. Tight glucose control reduces microvascular complications and adverse cardiovascular events. Insulin therapy is essential for such patients, but has shortcomings: a) only 1 in 3 patients achieve targeted glucose control ...
STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health -
Development of a novel accurate therapy for multiple sclerosis
SBC: Autoimmunity Biologic Solutions, Inc. Topic: NIAIDPROJECT SUMMARYMultiple Sclerosis (MS) is the most common neurological disease of early adulthood and is mediated by autoimmune mechanisms that lead to demyelination and neuronal damage in the central nervous system, resulting in progressive neurological dysfunction. Up to date, there is no cure for this devastating disease and current available treatments focus on preventing future immunological ...
STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health -
Simple Method for Screening of HIV Drug Resistance in Resource-Limited Settings
SBC: Discidium Biosciences, LLC Topic: NIAIDAbstract Drug resistance to antiretroviral therapy for HIV infection is a serious clinical problem without cost-effective solutions in low and middle-income countries (LMICs) where standard genotypic resistance assays are unaffordable. Discidiumandapos;s goal is to develop a single tube assay that uses lyophilized reactants, standard PCR and in-tube readout, that can be used as a screening resista ...
STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health -
Preclinical testing of a 3D printed external scaffold device to prevent vein graft failure after coronary bypass graft surgery
SBC: BIOGRAFT, INC. Topic: NHLBISaphenous vein graft (SVG) failure following coronary artery bypass grafting (CABG) is a critical clinical problem, with recent studies revealing that as many as 25% of vein grafts develop stenosis within 12-18 months after surgery, and up to 50% of grafts occlude within 5-10 years. CABG surgery is the gold standard treatment for patients with severe multi-vessel disease, with over 370,000 procedu ...
STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health -
Point-of-care microdevices for simultaneous detection of multiple pertussis-like respiratory diseases from Bordetella species
SBC: MICROBIOCHIP DIAGNOSTICS LLC Topic: NIAIDABSTRACT Pertussis, also known as whooping cough, caused by B. pertussis and B. parapertussis, is the only vaccine-preventable infection that remains endemic in the U.S. Since pertussis vaccine- induced immunity is not permanent, the immunized host is vulnerable to re-infection later in life. Worldwide, there are an estimated 24.1 million cases of pertussis, and about 160,700 deaths per year from ...
STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health -
A rapid test for congenital syphilis screening
SBC: MelioLabs Inc. Topic: NICHDPROJECT SUMMARY Since 2014, Congenital Syphilis (CS) cases in the United States, caused by the transplacental transmission of the bacterium Treponema pallidum from mother to child, have increased at an alarming rate. Targeted surveillance studies indicate a rise andgt;185% from 2014 to 2018 alone. Women who acquire syphilis within 4 years of pregnancy will transmit the infection to 80% of their fe ...
STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health -
Solving Sepsis: Early Identification and Prompt Management Using Machine Learning
SBC: Cohere-Med, Inc. Topic: 300Abstract This fast-track STTR application proposes to enhance, validate, and scale Sepsis Watch, a deep learning sepsis detection and management system built using data from the Emergency Department (ED) Duke University Hospital (DUH). The proposal will extend and enhance Sepsis Watch to EDs, general inpatient wards, and intensive care unit (ICU) settings across multiple health systems in the Unit ...
STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health -
Design and Engineering of Biodegradable 3D Nanoprinted Microcarriers for HIV Drug Delivery
SBC: INFRATRAC INC Topic: NIAIDPrecise, customizable drug delivery remains a long-term goal, for HIV in particular, as such technologies would allow therapies tailored to a patient’s biological makeup and potentially improve adherence. Extended-release methods address part of the issue, but face limitations. A novel drug delivery system could offer better pediatric dosing, via both oral and new routes of administration. Exist ...
STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health